Reference:ICH ICH E2F Guideline 2010 1: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 4: | Line 4: | ||
|RefDocPart=1 | |RefDocPart=1 | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00068-Dev-gsb ++ TAG-00317-Obj-set ++ TAG-00329-Saf-lne ++ TAG-00001-Med-rzn | ||
| | |RefModule=5 | ||
| | |RefUnit=5.3.3 | ||
}} | }} | ||
| Line 14: | Line 14: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 5 — Unit 5.3.3 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 30: | Line 33: | ||
| | | | ||
|- | |- | ||
! Tags | ! Tags | ||
| | | [[Glossary:TAG-00068-Dev-gsb|DSUR]], [[Glossary:TAG-00317-Obj-set|Objective]], [[Glossary:TAG-00329-Saf-lne|Safety]], [[Glossary:TAG-00001-Med-rzn|Medicinal product]] | ||
|- | |||
| | |||
|- | |||
| | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | ICH ICH E2F Guideline 2010 |
| Validity area | ICH |
| Scope(s) | G |
| Document name | ICH E2F Guideline |
| Version / Revision | 2010 |
| Status | Current |
| Document type | International guideline |
| Language(s) | EN |
| Description | DEVELOPMENT SAFETY UPDATE REPORT |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 5 — Unit 5.3.3 |
| Scope | G |
| Document part | 1 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | DSUR, Objective, Safety, Medicinal product |
| Comment | DSUR: purpose and intended use as periodic safety report |
Content
The Development Safety Update Report (DSUR) proposed in this guideline is intended to be a common standard for periodic reporting on drugs under development (including marketed drugs that are under further study) among the ICH regions […]
1.2 Objectives The main objective of a DSUR is to present a comprehensive, thoughtful annual review and evaluation of pertinent safety information collected during the reporting period related to a drug under investigation, whether or not it is marketed [...]
